Tolerability of Fluoroquinolone Antibiotics: Past, Present and Future

Drug Safety

Volumn 13, Issue 6, 1995, Pages 343-358

  Ball, Peter ^a   Tillotson, Glenn ^b  

^a VICTORIA HOSPITAL   (United Kingdom)

^b Bayer plc UK   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CIPROFLOXACIN; ENOXACIN; FLEROXACIN; LEVOFLOXACIN; LOMEFLOXACIN; NORFLOXACIN; OFLOXACIN; PEFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SPARFLOXACIN;

ANAPHYLAXIS; BRAIN PSEUDOTUMOR; CARDIOTOXICITY; CENTRAL NERVOUS SYSTEM DISEASE; CHEMICAL STRUCTURE; CONVULSION; CRYSTALLURIA; DIARRHEA; DRUG STRUCTURE; DRUG TOLERANCE; GASTROINTESTINAL SYMPTOM; HEMOLYSIS; HEPATITIS; HUMAN; INSOMNIA; INTERSTITIAL NEPHRITIS; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY FAILURE; KIDNEY INJURY; LIVER INJURY; MAJOR CLINICAL STUDY; NEPHROTOXICITY; NEUROTOXICITY; ORAL DRUG ADMINISTRATION; PHOTOTOXICITY; PRIORITY JOURNAL; PRURITUS; PSEUDOMEMBRANOUS COLITIS; PSYCHOSIS; RASH; REVIEW; SERUM SICKNESS; SOMNOLENCE; TENDINITIS; VASCULITIS; VERTIGO;

ANTI-INFECTIVE AGENTS, FLUOROQUINOLONE; DRUG INTERACTIONS; HUMAN;

EID: 0028818518     PISSN: 01145916     EISSN: 11791942     Source Type: Journal    
DOI: 10.2165/00002018-199513060-00004     Document Type: Review

References (130)

1. Structure-activity and structure-side-effect relationships for the quinolone antibacterials
2. Ciprofloxacin: review of potential toxicologic effects
3. Reactions to nalidixic acid
4. Intracranial hypertension in a child during treatment with nalidixic acid
5. Nalidixic acid
6. Fatal acute immune haemolytic anaemia caused by nalidixic acid
7. Drug interactions with quinolones
8. Temafloxacin syndrome: review of 95 cases
9. Overview of post-marketing experience with ofloxacin in Germany
10. The influence of quinolone derivatives on theophylline clearance
11. Drug-drug interactions with ciprofloxacin and other fluoroquinolones
12. Levofloxacin: a review of its antibacterial activity, pharmacokinetics and therapeutic efficacy
13. Long term use of quinolones and their safety
14. Safety profile of ciprofloxacin during long-term therapy for pulmonary tuberculosis
15. Ciprofloxacin: an overview of adverse experiences
16. Assessment of adverse events during drug development: experience with temafloxacin
17. Safety of fleroxacin in clinical trials
18. Efficacy and safety of ofloxacin in elderly patients
19. Temafloxacin: a safe antibiotic for the elderly, patients with co-morbidities, and other special populations
20. Post-marketing surveillance of levofloxacin in Japan
21. Adverse reactions associated with quinolones
22. World-wide experience with norfloxacin: efficacy and safety
23. Pefloxacin: a review of its antibacterial activity, pharmacokinetic properties and therapeutic use
24. Worldwide clinical data on efficacy and safety of ciprofloxacin
25. Coordinated multicenter study of norfloxacin versus trimethoprim-sulphamethoxazole treatment of symptomatic urinary tract infection
26. The use of fluoroquinolones in neutropenic patients: analysis of adverse effects
27. Ciprofloxacin safety relative to temafloxacin and lomefloxacin
28. Reduced phototoxicity of a fluoroquinolone antibacterial agent with a methoxy group at the 8 position in mice irradiated with long-wavelength UV light
29. Efficacy of lomefloxacin as compared to norfloxacin in the treatment of uncomplicated urinary tract infections in adults
30. Lomefloxacin-induced photodermatosis
31. Integrated safety profile of intravenous ciprofloxacin
32. Challenges in the development of intravenous ciprofloxacin
33. The selection of appropriate dosages for intravenous ciprofloxacin
34. Overview of fluoroquinolone safety
35. Safety of ofloxacin: adverse drug reactions reported during Phase-II studies in Europe and Japan
36. Clostridium difficile colitis associated with ofloxacin therapy
37. Clostridium difficile associated diarrhoea after norfloxacin
38. Pseudomembranous colitis associated with ciprofloxacin
39. Ciprofloxacin and Clostridium difficile-associated diarrhoea
40. Norfloxacin-induced hepatotoxicity
41. Ofloxacin-induced acute severe hepatitis
42. Suspected ciprofloxacin-induced hepatotoxicity
43. A follow-up safety study of ciprofloxacin users
44. Side effects of ofloxacin in clinical trials and post-marketing surveillance
45. Quinolones and raised plasma concentrations of theophylline
46. Overview of drug interactions with the quinolones
47. PEM Report Number 4
48. Grand mal seizures as a complication of treatment with pefloxacin in patients with cirrhosis
49. Treatment of severe pneumonia in hospitalised patients: results of a multi-center, randomised, double-blind trial comparing intravenous ciprofloxacin with imipenem-cilastatin
50. Accidental overdose of ofloxacin with benign outcome
51. Massive intoxication by flumequine
52. Pharmacokinetics of ofloxacin and theophylline alone and in combination
53. Effect of levofloxacin on serum concentration of theophylline
54. Effect of the new quinolone, sparfloxacin, on the pharmacokinetics of theophylline in asthmatic patients
55. An evaluation of the quinolone-theophylline interaction using the FDA spontaneous reporting system
56. Inhibition of the oxidative mechanism of theophylline in isolated rat hepatocytes by the quinolone antibiotic enoxacin and its metabolite oxo-enoxacin, but not by ofloxacin
57. The possible mechanism of interaction between xanthines and quinolone
58. In vitro effect of fluoroquinolones on theophylline metabolism in human liver microsomes
59. Unusual CNS toxic action of new quinolones
60. Effect of new 4-quinolones on gamma-amino butyric acid receptor binding
61. Central nervous system toxicity of quinolones: human and animal findings
62. Interaction of the new quinolone antibacterial agent levofloxacin with fenbufen in mice
63. Ciprofloxacin and sparfloxacin penetration into human brain tissue and their activity as antagonists of GABA receptor of rat vagus nerve
64. Comparison of the inhibitory effects of new quinolones on γ-aminobutyric acid receptor binding in the presence of anti-inflammatory drugs
65. Antagonism of GABA receptors by 4-quinolones
66. Hippocampal activity in the presence of quinolones and fenbufen. in vitro
67. Adverse reactions in a dose ranging study with a new long acting fluoroquinolone
68. Decrease of caffeine elimination in man during co-administration of 4-quinolones
69. Overview of clinical experience with ciprofloxacin
70. Benign intracranial hypertension after ciprofloxacin administration
71. Adverse effects
72. Photosensitivity associated with antibacterial agents
73. Phototoxic reaction with nalidixic acid
74. Nalidixic acid-induced photodermatitis after minimal sun exposure
75. Ciprofloxacin induced photosensitivity: in vitro and in vivo studies
76. Clinical and laboratory studies of the photosensitising potential of norfloxacin, a 4-quinolone broad spectrum antibiotic
77. Clinical features and management of adverse effects of quinolone antibacterials
78. Phototoxic potential of the new quinolone antibacterial agent levofloxacin in mice
79. Photosensitivity associated with ciprofloxacin use in adult patients with cystic fibrosis
80. Photo-onycholysis induced by the fluoroquinolones pefloxacin and ofloxacin
81. Crystalluria and ciprofloxacin, influence of urinary pH and hydration
82. Norfloxacin disposition after sequentially increasing oral doses
83. Ciprofloxacin-induced haematuria
84. Overview of toxicological studies
85. Acute renal failure secondary to oral ciprofloxacin therapy: a presentation of three cases and a review of the literature
86. Case report of renal failure during norfloxacin therapy
87. Ciprofloxacin and allergic interstitial nephritis
88. Allergic nephropathy associated with ciprofloxacin
89. Acute renal failure due to ciprofloxacin
90. Ciprofloxacininduced nephrotoxicity in patients with cancer
91. Ciprofloxacin nephrotoxicity
92. Norfloxacin induced nephrotic syndrome
93. Anaphylactoid reactions reported after treatment with ciprofloxacin
94. Anaphylactoid drug reactions to ciprofloxacin and rifampicin in HIV-infected patients
95. Anaphylactoid reactions to ciprofloxacin in cystic fibrosis patients
96. Ciprofloxacin-induced anaphylactoid reactions in patients infected with the human immunodeficiency virus
97. Hypersensitivity vasculitis due to ofloxacin
98. Ciprofloxacin-induced vasculitis
99. Cutaneous vasculitis due to ciprofloxacin
100. Serum sickness-like illness associated with ciprofloxacin
101. Arthropathy induced by antibacterial fused N-alkyl-4-pyridone-3-carboxylic acids
102. Arthropathy in a patient with cystic fibrosis taking ciprofloxacin
103. Lack of quinolone-induced arthropathy in children
104. Severe arthropathy in an adolescent treated with pefloxacin
105. A case of destructive polyarthropathy in a 17-year-old youth following pefloxacin treatment
106. The arthropathy of cystic fibrosis
107. Joint tolerance of pefloxacin and ofloxacin in children and teenagers with cystic fibrosis
108. Safety of ciprofloxacin in children: worldwide experience based on compassionate use, emphasis on joint evaluation
109. Nalidixic acid in children: retrospective matched case controlled study for cartilage toxicity
110. Growth and joint symptoms in children treated with nalidixic acid
111. Clinical, radiologic and magnetic resonance monitoring for skeletal toxicity in paediatric patients with cystic fibrosis receiving a three month course of ciprofloxacin
112. Morphologic studies for skeletal toxicity after prolonged ciprofloxacin therapy in two juvenile cystic fibrosis patients
113. The effects on growth of single short courses of fluoroquinolones
114. Role of the new quinolones in paediatric practice
115. Use of fluoroquinolones in paediatrics: consensus report of an International Society of Chemotherapy commission
116. Features of tendon disorders with fluoroquinolones
117. Seven Achilles tendonitis including 3 complicated by rupture during fluoroquinolone therapy
118. Ciprofloxacin associated bilateral achilles tendon rupture
119. More on fluoroquinolone antibiotics and tendon rupture
120. More on fluoroquinolone antibiotics and tendon rupture
121. Possible exacerbation of myasthenia gravis by ciprofloxacin
122. Exacerbation of myasthenia gravis by norfloxacin
123. Probable exacerbation of myasthenia gravis by ofloxacin
124. Ciprofloxacin in neonates and its possible adverse effect on the teeth
125. Postmarketing surveillance of quinolones, 1990 to 1992